GA CoV-2 IgM EIA
GA-CoV-2 ELISA diagnostic workflow includes 3 screens for all immunodominant proteins of SARS-CoV-2 (N, S1, S2) achieving an overall specificity of 99%. The round of the screening includes both IgM and IgG with a sensitivity of 98% ten days post infection.
The GA CoV-2 IgG+ confirmatory test offers reliable support to differentiate other coronavirus infections and aids in the assessment of immune protection. Following a positive antibody result in screening, virus-specific antibodies against the N, S1 and S2 proteins are determined using this confirmatory test. It is known that antibodies to the nucleocapsid (N) protein, may have been generated during a previous SARS or MERS infection. By confirming double positivity, and the confirmation of S1 or S2 antibodies specifically, we increased the specificity in our clinical trial to 99%.